Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen

Heidary et al., The Journal of Antibiotics, 73, 593–602, doi:10.1038/s41429-020-0336-z
Jun 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
Review of the antimicrobial, antiviral, and anti-cancer properties of ivermectin.
Antiviral effects have been reported for Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2.
Ivermectin plays a role in several biological mechanisms, therefore it could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19 as well as other types of positive-sense single-stranded RNA viruses. In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin, however, clinical trials are necessary to appraise the potential efficacy of ivermectin in clinical setting.
Reviews covering ivermectin for COVID-19 include1-41.
Heidary et al., 12 Jun 2020, peer-reviewed, 2 authors.
This PaperIvermectinAll
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
Fatemeh Heidary, Reza Gharebaghi
The Journal of Antibiotics, doi:10.1038/s41429-020-0336-z
Ivermectin proposes many potentials effects to treat a range of diseases, with its antimicrobial, antiviral, and anti-cancer properties as a wonder drug. It is highly effective against many microorganisms including some viruses. In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies over the past 50 years. Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2. Furthermore, there are some studies showing antiviral effects of ivermectin against DNA viruses such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1. Ivermectin plays a role in several biological mechanisms, therefore it could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19 as well as other types of positive-sense single-stranded RNA viruses. In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin, however, clinical trials are necessary to appraise the potential efficacy of ivermectin in clinical setting.
Conflict of interest The authors declare that they have no conflict of interest. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Ang, Lee, Choi, Zhang, Lee, Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines, Integr Med Res, doi:10.1016/j.imr.2020.100407.
Atkinson, Audsley, Lieu, Recognition by host nuclear transport proteins drives disorder-to-order transition in Hendra virus V, Sci Rep, doi:10.1038/s41598-017-18742-8
Azeem, Ashraf, Rasheed, Anjum, Hameed, Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus, Pak J Pharm Sci
Baron, Devaux, Colson, Raoult, Rolain, Teicoplanin: an alternative drug for the treatment of COVID-19?, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105944
Barrows, Campos, Powell, A screen of FDAapproved drugs for inhibitors of Zika virus infection, Cell Host Microbe, doi:10.1016/j.chom.2016.07.004.
Bennett, Zhao, Bosard, Imperiale, Role of a nuclear localization signal on the minor capsid proteins VP2 and VP3 in BKPyV nuclear entry, Virology, doi:10.1016/j.virol.2014.10.013.
Berthomme, Monahan, Parris, Jacquemont, Epstein, Cloning, sequencing, and functional characterization of the two subunits of the pseudorabies virus DNA polymerase holoenzyme: evidence for specificity of interaction, J Virol
Caly, Druce, Catton, Jans, Wagstaff, The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Canga, Prieto, Liébana, Martínez, Vega et al., The pharmacokinetics and interactions of ivermectin in humans-a mini-review, AAPS J
Croci, Bottaro, Chan, Liposomal systems as nanocarriers for the antiviral agent ivermectin, Int J Biomater, doi:10.1155/2016/8043983.
Crump, Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations, J Antibiot
Crump, Ōmura, Ivermectin, 'wonder drug' from Japan: the human use perspective, Proc Jpn Acad Ser B Phys Biol Sci, doi:10.2183/pjab.87.13
Fraser, Rawlinson, Wang, Jans, Wagstaff, Investigating dengue virus nonstructural protein 5 (NS5) nuclear import, Methods Mol Biol, doi:10.1007/978-1-4939-0348-1_19.
Ge, Li, Yang, Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor, Nature, doi:10.1038/nature12711.
Gharebaghi, Heidary, COVID-19 and Iran: swimming with hands tied!, Swiss Med Wkly, doi:10.4414/smw.2020.20242.
Gharebaghi, Heidary, Moradi, Parvizi, Metronidazole; a potential novel addition to the COVID-19 treatment regimen, Arch Academic Emerg Med
Gonzalez Canga, Prieto, Liebana, Martinez, Vega et al., The pharmacokinetics and interactions of ivermectin in humans-a mini-review, AAPS J, doi:10.1208/s12248-007-9000-9.
Gotz, Magar, Dornfeld, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci Rep, doi:10.1038/srep23138.
Ji, Luo, Zika virus NS5 nuclear accumulation is protective of protein degradation and is required for viral RNA replication, Virology, doi:10.1016/j.virol.2019.10.010.
Ketkar, Yang, Wormser, Wang, Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system, Diagn Microbiol Infect Dis, doi:10.1016/j.diagmicrobio.2019.03.012.
Khalil, Samrah, In vivo combined treatment of rats with ivermectin and aged garlic extract attenuates ivermectininduced cytogenotoxicity in bone marrow cells, Res Vet Sci, doi:10.1016/j.rvsc.2018.09.005.
Kircik, Rosso, Layton, Schauber, Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications, J Drugs Dermatol
Kosyna, Nagel, Kluxen, Kraushaar, Depping, The importin alpha/beta-specific inhibitor Ivermectin affects HIFdependent hypoxia response pathways, Biol Chem, doi:10.1515/hsz-2015-0171.
Laing, Devaney, Ivermectin-old drug, new tricks?, Trends Parasitol, doi:10.1016/j.pt.2017.02.004.
Lee, Lee, Ivermectin inhibits porcine reproductive and respiratory syndrome virus in cultured porcine alveolar macrophages, Arch Virol, doi:10.1007/s00705-015-2653-2.
Lu, Chang, Potential therapeutic agents against what we know so far, J Chin Med Assoc, doi:10.1097/JCMA.0000000000000318
Lu, Stratton, Tang, Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle, J Med Virol, doi:10.1002/jmv.25678.
Lundberg, Pinkham, Baer, Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan equine encephalitis virus replication, Antivir Res, doi:10.1016/j.antiviral.2013.10.004.
Lv, Liu, Wang, Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antivir Res, doi:10.1016/j.antiviral.2018.09.010.
Mastrangelo, Pezzullo, Burghgraeve, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J Antimicrob Chemother, doi:10.1093/jac/dks147.
Raza, Zhai, Ivermectin inhibits bovine herpesvirus 1 DNA polymerase nuclear import and interferes with viral replication, Microorganisms, doi:10.3390/microorganisms8030409
Reviglio, Osaba, Reviglio, Chiaradia, Kuo, COVID-19 and ophthalmology: a new chapter in an old story, Med Hypothesis Disco Innov Ophthalmol
Shechter, Thomas, Lundberg, Novel inhibitors targeting Venezuelan equine encephalitis virus capsid protein identified using in silico structure-based-drug-design, Sci Rep, doi:10.1038/s41598-017-17672-9.
Slonska, Cymerys, Skwarska, Golke, Banbura, Influence of importin alpha/beta and exportin 1 on equine herpesvirus type 1 (EHV-1) replication in primary murine neurons, Pol J Vet Sci, doi:10.2478/pjvs-2013-0106.
Sohrabi, Alsafi, Neill, World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19), Int J Surg, doi:10.1016/j.ijsu.2020.02.034.
Surnar, Kamran, Shah, Orally administrable therapeutic synthetic nanoparticle for Zika virus, ACS Nano, doi:10.1021/acsnano.9b02807.
Tay, Fraser, Chan, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir Res, doi:10.1016/j.antiviral.2013.06.002.
Varghese, Kaukinen, Glasker, Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antivir Res, doi:10.1016/j.antiviral.2015.12.012.
Wagstaff, Rawlinson, Hearps, Jans, An AlphaScreen(R)-based assay for high-throughput screening for specific inhibitors of nuclear import, J Biomol Screen, doi:10.1177/1087057110390360.
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J, doi:10.1042/BJ20120150.
Wang, Du, Huang, The pseudorabies virus DNA polymerase accessory subunit UL42 directs nuclear transport of the holoenzyme, Front Microbiol, doi:10.3389/fmicb.2016.00124.
Wang, Lv, Wang, Qiu, Yang, Ivermectin treatment inhibits the replication of Porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets, Virus Res, doi:10.1016/j.virusres.2019.01.010.
Yang, Atkinson, Wang, The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer, Antivir Res, doi:10.1016/j.antiviral.2020.104760.
Yang, Hu, Wang, Isolation and characterization of a novel bat coronavirus closely related to the direct progenitor of severe acute respiratory syndrome coronavirus, J Virol, doi:10.1128/JVI.02582-15.
{ 'indexed': {'date-parts': [[2024, 5, 13]], 'date-time': '2024-05-13T13:24:40Z', 'timestamp': 1715606680287}, 'reference-count': 45, 'publisher': 'Springer Science and Business Media LLC', 'issue': '9', 'license': [ { 'start': { 'date-parts': [[2020, 6, 12]], 'date-time': '2020-06-12T00:00:00Z', 'timestamp': 1591920000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2020, 6, 12]], 'date-time': '2020-06-12T00:00:00Z', 'timestamp': 1591920000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 9]]}, 'DOI': '10.1038/s41429-020-0336-z', 'type': 'journal-article', 'created': {'date-parts': [[2020, 6, 12]], 'date-time': '2020-06-12T09:04:12Z', 'timestamp': 1591952652000}, 'page': '593-602', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 225, 'title': 'Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen', 'prefix': '10.1038', 'volume': '73', 'author': [ {'given': 'Fatemeh', 'family': 'Heidary', 'sequence': 'first', 'affiliation': []}, {'given': 'Reza', 'family': 'Gharebaghi', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2020, 6, 12]]}, 'reference': [ { 'key': '336_CR1', 'doi-asserted-by': 'publisher', 'first-page': '13', 'DOI': '10.2183/pjab.87.13', 'volume': '87', 'author': 'A Crump', 'year': '2011', 'unstructured': 'Crump A, Ōmura S. Ivermectin, ‘wonder drug’ from Japan: the human use ' 'perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:13–28. ' 'https://doi.org/10.2183/pjab.87.13.', 'journal-title': 'Proc Jpn Acad Ser B Phys Biol Sci.'}, { 'key': '336_CR2', 'first-page': '325', 'volume': '15', 'author': 'LH Kircik', 'year': '2016', 'unstructured': 'Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of ' 'clinical experience with ivermectin: an overview of safety for an ' 'increasing number of indications. J Drugs Dermatol. 2016;15:325–32.', 'journal-title': 'J Drugs Dermatol'}, { 'key': '336_CR3', 'doi-asserted-by': 'publisher', 'first-page': '42', 'DOI': '10.1208/s12248-007-9000-9.', 'volume': '10', 'author': 'A Gonzalez Canga', 'year': '2008', 'unstructured': 'Gonzalez Canga A, Sahagun Prieto AM, Diez Liebana MJ, Fernandez Martinez ' 'N, Sierra Vega M, Garcia Vieitez JJ. The pharmacokinetics and ' 'interactions of ivermectin in humans–a mini-review. AAPS J. ' '2008;10:42–6. https://doi.org/10.1208/s12248-007-9000-9.', 'journal-title': 'AAPS J.'}, { 'key': '336_CR4', 'doi-asserted-by': 'publisher', 'first-page': '463', 'DOI': '10.1016/j.pt.2017.02.004.', 'volume': '33', 'author': 'R Laing', 'year': '2017', 'unstructured': 'Laing R, Gillan V, Devaney E. Ivermectin—old drug, new tricks? Trends ' 'Parasitol. 2017;33:463–72. https://doi.org/10.1016/j.pt.2017.02.004.', 'journal-title': 'Trends Parasitol.'}, { 'key': '336_CR5', 'doi-asserted-by': 'publisher', 'first-page': '71', 'DOI': '10.1016/j.ijsu.2020.02.034.', 'volume': '76', 'author': 'C Sohrabi', 'year': '2020', 'unstructured': 'Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization ' 'declares global emergency: a review of the 2019 novel coronavirus ' '(COVID-19). Int J Surg. 2020;76:71–6. ' 'https://doi.org/10.1016/j.ijsu.2020.02.034.', 'journal-title': 'Int J Surg.'}, { 'key': '336_CR6', 'doi-asserted-by': 'publisher', 'first-page': '401', 'DOI': '10.1002/jmv.25678.', 'volume': '92', 'author': 'H Lu', 'year': '2020', 'unstructured': 'Lu H, Stratton CW, Tang Y-W. Outbreak of pneumonia of unknown etiology ' 'in Wuhan, China: the mystery and the miracle. J Med Virol. ' '2020;92:401–2. https://doi.org/10.1002/jmv.25678.', 'journal-title': 'J Med Virol'}, { 'key': '336_CR7', 'doi-asserted-by': 'publisher', 'first-page': '535', 'DOI': '10.1038/nature12711.', 'volume': '503', 'author': 'X-Y Ge', 'year': '2013', 'unstructured': 'Ge X-Y, Li J-L, Yang X-L, et al. Isolation and characterization of a bat ' 'SARS-like coronavirus that uses the ACE2 receptor. Nature. ' '2013;503:535–8. https://doi.org/10.1038/nature12711.', 'journal-title': 'Nature.'}, { 'key': '336_CR8', 'doi-asserted-by': 'publisher', 'first-page': '3253', 'DOI': '10.1128/JVI.02582-15.', 'volume': '90', 'author': 'X-L Yang', 'year': '2015', 'unstructured': 'Yang X-L, Hu B, Wang B, et al. Isolation and characterization of a novel ' 'bat coronavirus closely related to the direct progenitor of severe acute ' 'respiratory syndrome coronavirus. J Virol. 2015;90:3253–6. ' 'https://doi.org/10.1128/JVI.02582-15.', 'journal-title': 'J Virol.'}, { 'key': '336_CR9', 'doi-asserted-by': 'publisher', 'unstructured': 'Lu C-C, Chen M-Y, Chang Y-L. Potential therapeutic agents against ' 'COVID-19: what we know so far. J Chin Med Assoc. 2020. ' 'https://doi.org/10.1097/JCMA.0000000000000318.', 'DOI': '10.1097/JCMA.0000000000000318'}, { 'key': '336_CR10', 'doi-asserted-by': 'publisher', 'first-page': '100407.', 'DOI': '10.1016/j.imr.2020.100407.', 'volume': '9', 'author': 'L Ang', 'year': '2020', 'unstructured': 'Ang L, Lee HW, Choi JY, Zhang J, Soo Lee M. Herbal medicine and pattern ' 'identification for treating COVID-19: a rapid review of guidelines. ' 'Integr Med Res. 2020;9:100407. ' 'https://doi.org/10.1016/j.imr.2020.100407.', 'journal-title': 'Integr Med Res.'}, { 'key': '336_CR11', 'first-page': 'e40', 'volume': '8', 'author': 'R Gharebaghi', 'year': '2020', 'unstructured': 'Gharebaghi R, Heidary F, Moradi M, Parvizi M. Metronidazole; a potential ' 'novel addition to the COVID-19 treatment regimen. Arch Academic Emerg ' 'Med. 2020;8:e40.', 'journal-title': 'Arch Academic Emerg Med'}, { 'key': '336_CR12', 'doi-asserted-by': 'publisher', 'unstructured': 'Baron SA, Devaux C, Colson P, Raoult D, Rolain J-M. Teicoplanin: an ' 'alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. ' '2020:105944. https://doi.org/10.1016/j.ijantimicag.2020.105944.', 'DOI': '10.1016/j.ijantimicag.2020.105944'}, { 'key': '336_CR13', 'doi-asserted-by': 'publisher', 'first-page': 'w20242.', 'DOI': '10.4414/smw.2020.20242.', 'volume': '150', 'author': 'R Gharebaghi', 'year': '2020', 'unstructured': 'Gharebaghi R, Heidary F. COVID-19 and Iran: swimming with hands tied! ' 'Swiss Med Wkly. 2020;150:w20242. https://doi.org/10.4414/smw.2020.20242.', 'journal-title': 'Swiss Med Wkly'}, { 'key': '336_CR14', 'first-page': '71', 'volume': '9', 'author': 'VE Reviglio', 'year': '2020', 'unstructured': 'Reviglio VE, Osaba M, Reviglio V, Chiaradia P, Kuo IC. COVID-19 and ' 'ophthalmology: a new chapter in an old story. Med Hypothesis Disco Innov ' 'Ophthalmol. 2020;9:71–3.', 'journal-title': 'Med Hypothesis Disco Innov Ophthalmol'}, { 'key': '336_CR15', 'doi-asserted-by': 'publisher', 'unstructured': 'Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ' 'ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral ' 'Res. 2020:104787. https://doi.org/10.1016/j.antiviral.2020.104787.', 'DOI': '10.1016/j.antiviral.2020.104787'}, { 'key': '336_CR16', 'doi-asserted-by': 'publisher', 'first-page': '259', 'DOI': '10.1016/j.chom.2016.07.004.', 'volume': '20', 'author': 'NJ Barrows', 'year': '2016', 'unstructured': 'Barrows NJ, Campos RK, Powell ST, et al. A screen of FDA-approved drugs ' 'for inhibitors of Zika virus infection. Cell Host Microbe. ' '2016;20:259–70. https://doi.org/10.1016/j.chom.2016.07.004.', 'journal-title': 'Cell Host Microbe'}, { 'key': '336_CR17', 'doi-asserted-by': 'publisher', 'first-page': '38', 'DOI': '10.1016/j.diagmicrobio.2019.03.012.', 'volume': '95', 'author': 'H Ketkar', 'year': '2019', 'unstructured': 'Ketkar H, Yang L, Wormser GP, Wang P. Lack of efficacy of ivermectin for ' 'prevention of a lethal Zika virus infection in a murine system. Diagn ' 'Microbiol Infect Dis. 2019;95:38–40. ' 'https://doi.org/10.1016/j.diagmicrobio.2019.03.012.', 'journal-title': 'Diagn Microbiol Infect Dis'}, { 'key': '336_CR18', 'doi-asserted-by': 'publisher', 'first-page': '94', 'DOI': '10.1016/j.rvsc.2018.09.005.', 'volume': '120', 'author': 'AM Khalil', 'year': '2018', 'unstructured': 'Khalil AM, Abu Samrah HM. In vivo combined treatment of rats with ' 'ivermectin and aged garlic extract attenuates ivermectin-induced ' 'cytogenotoxicity in bone marrow cells. Res Vet Sci. 2018;120:94–100. ' 'https://doi.org/10.1016/j.rvsc.2018.09.005.', 'journal-title': 'Res Vet Sci'}, { 'key': '336_CR19', 'doi-asserted-by': 'publisher', 'first-page': '124', 'DOI': '10.1016/j.virol.2019.10.010.', 'volume': '541', 'author': 'W Ji', 'year': '2020', 'unstructured': 'Ji W, Luo G. Zika virus NS5 nuclear accumulation is protective of ' 'protein degradation and is required for viral RNA replication. Virology. ' '2020;541:124–35. https://doi.org/10.1016/j.virol.2019.10.010.', 'journal-title': 'Virology.'}, { 'key': '336_CR20', 'doi-asserted-by': 'publisher', 'first-page': '301', 'DOI': '10.1016/j.antiviral.2013.06.002.', 'volume': '99', 'author': 'MYF Tay', 'year': '2013', 'unstructured': 'Tay MYF, Fraser JE, Chan WKK, et al. Nuclear localization of dengue ' 'virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV ' 'serotypes by the inhibitor Ivermectin. Antivir Res. 2013;99:301–6. ' 'https://doi.org/10.1016/j.antiviral.2013.06.002.', 'journal-title': 'Antivir Res.'}, { 'key': '336_CR21', 'doi-asserted-by': 'publisher', 'first-page': '851', 'DOI': '10.1042/BJ20120150.', 'volume': '443', 'author': 'KM Wagstaff', 'year': '2012', 'unstructured': 'Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is ' 'a specific inhibitor of importin alpha/beta-mediated nuclear import able ' 'to inhibit replication of HIV-1 and dengue virus. Biochem J. ' '2012;443:851–6. https://doi.org/10.1042/BJ20120150.', 'journal-title': 'Biochem J.'}, { 'key': '336_CR22', 'doi-asserted-by': 'publisher', 'first-page': '11034', 'DOI': '10.1021/acsnano.9b02807.', 'volume': '13', 'author': 'B Surnar', 'year': '2019', 'unstructured': 'Surnar B, Kamran MZ, Shah AS, et al. Orally administrable therapeutic ' 'synthetic nanoparticle for Zika virus. ACS Nano. 2019;13:11034–48. ' 'https://doi.org/10.1021/acsnano.9b02807.', 'journal-title': 'ACS Nano.'}, { 'key': '336_CR23', 'doi-asserted-by': 'publisher', 'first-page': '104760', 'DOI': '10.1016/j.antiviral.2020.104760.', 'volume': '177', 'author': 'SNY Yang', 'year': '2020', 'unstructured': 'Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ' 'ivermectin targets the host nuclear transport importin alpha/beta1 ' 'heterodimer. Antivir Res. 2020;177:104760. ' 'https://doi.org/10.1016/j.antiviral.2020.104760.', 'journal-title': 'Antivir Res.'}, { 'key': '336_CR24', 'doi-asserted-by': 'publisher', 'first-page': '1357', 'DOI': '10.1515/hsz-2015-0171.', 'volume': '396', 'author': 'FK Kosyna', 'year': '2015', 'unstructured': 'Kosyna FK, Nagel M, Kluxen L, Kraushaar K, Depping R. The importin ' 'alpha/beta-specific inhibitor Ivermectin affects HIF-dependent hypoxia ' 'response pathways. Biol Chem. 2015;396:1357–67. ' 'https://doi.org/10.1515/hsz-2015-0171.', 'journal-title': 'Biol Chem.'}, { 'key': '336_CR25', 'doi-asserted-by': 'publisher', 'first-page': '1884', 'DOI': '10.1093/jac/dks147.', 'volume': '67', 'author': 'E Mastrangelo', 'year': '2012', 'unstructured': 'Mastrangelo E, Pezzullo M, De Burghgraeve T, et al. Ivermectin is a ' 'potent inhibitor of flavivirus replication specifically targeting NS3 ' 'helicase activity: new prospects for an old drug. J Antimicrob ' 'Chemother. 2012;67:1884–94. https://doi.org/10.1093/jac/dks147.', 'journal-title': 'J Antimicrob Chemother'}, { 'key': '336_CR26', 'doi-asserted-by': 'publisher', 'first-page': '301', 'DOI': '10.1007/978-1-4939-0348-1_19.', 'volume': '1138', 'author': 'JE Fraser', 'year': '2014', 'unstructured': 'Fraser JE, Rawlinson SM, Wang C, Jans DA, Wagstaff KM. Investigating ' 'dengue virus nonstructural protein 5 (NS5) nuclear import. Methods Mol ' 'Biol. 2014;1138:301–28. https://doi.org/10.1007/978-1-4939-0348-1_19.', 'journal-title': 'Methods Mol Biol'}, { 'key': '336_CR27', 'doi-asserted-by': 'publisher', 'first-page': '8043983.', 'DOI': '10.1155/2016/8043983.', 'volume': '2016', 'author': 'R Croci', 'year': '2016', 'unstructured': 'Croci R, Bottaro E, Chan KWK, et al. Liposomal systems as nanocarriers ' 'for the antiviral agent ivermectin. Int J Biomater. 2016;2016:8043983. ' 'https://doi.org/10.1155/2016/8043983.', 'journal-title': 'Int J Biomater'}, { 'key': '336_CR28', 'doi-asserted-by': 'publisher', 'first-page': '358.', 'DOI': '10.1038/s41598-017-18742-8', 'volume': '8', 'author': 'SC Atkinson', 'year': '2018', 'unstructured': 'Atkinson SC, Audsley MD, Lieu KG. et al. Recognition by host nuclear ' 'transport proteins drives disorder-to-order transition in Hendra virus ' 'V. Sci Rep. 2018;8:358. https://doi.org/10.1038/s41598-017-18742-8.', 'journal-title': 'Sci Rep.'}, { 'key': '336_CR29', 'first-page': '597', 'volume': '28', 'author': 'S Azeem', 'year': '2015', 'unstructured': 'Azeem S, Ashraf M, Rasheed MA, Anjum AA, Hameed R. Evaluation of ' 'cytotoxicity and antiviral activity of ivermectin against Newcastle ' 'disease virus. Pak J Pharm Sci. 2015;28:597–602.', 'journal-title': 'Pak J Pharm Sci'}, { 'key': '336_CR30', 'doi-asserted-by': 'publisher', 'first-page': '662', 'DOI': '10.1016/j.antiviral.2013.10.004.', 'volume': '100', 'author': 'L Lundberg', 'year': '2013', 'unstructured': 'Lundberg L, Pinkham C, Baer A, et al. Nuclear import and export ' 'inhibitors alter capsid protein distribution in mammalian cells and ' 'reduce Venezuelan equine encephalitis virus replication. Antivir Res. ' '2013;100:662–72. https://doi.org/10.1016/j.antiviral.2013.10.004.', 'journal-title': 'Antivir Res.'}, { 'key': '336_CR31', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-017-17672-9.', 'volume': '7', 'author': 'S Shechter', 'year': '2017', 'unstructured': 'Shechter S, Thomas DR, Lundberg L, et al. Novel inhibitors targeting ' 'Venezuelan equine encephalitis virus capsid protein identified using in ' 'silico structure-based-drug-design. Sci Rep. 2017;7:17705. ' 'https://doi.org/10.1038/s41598-017-17672-9.', 'journal-title': 'Sci Rep.'}, { 'key': '336_CR32', 'doi-asserted-by': 'publisher', 'first-page': '117', 'DOI': '10.1016/j.antiviral.2015.12.012.', 'volume': '126', 'author': 'FS Varghese', 'year': '2016', 'unstructured': 'Varghese FS, Kaukinen P, Glasker S, et al. Discovery of berberine, ' 'abamectin and ivermectin as antivirals against chikungunya and other ' 'alphaviruses. Antivir Res. 2016;126:117–24. ' 'https://doi.org/10.1016/j.antiviral.2015.12.012.', 'journal-title': 'Antivir Res.'}, { 'key': '336_CR33', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/srep23138.', 'volume': '6', 'author': 'V Gotz', 'year': '2016', 'unstructured': 'Gotz V, Magar L, Dornfeld D, et al. Influenza A viruses escape from MxA ' 'restriction at the expense of efficient nuclear vRNP import. Sci Rep. ' '2016;6:23138. https://doi.org/10.1038/srep23138.', 'journal-title': 'Sci Rep.'}, { 'key': '336_CR34', 'doi-asserted-by': 'publisher', 'first-page': '257', 'DOI': '10.1007/s00705-015-2653-2.', 'volume': '161', 'author': 'YJ Lee', 'year': '2016', 'unstructured': 'Lee YJ, Lee C. Ivermectin inhibits porcine reproductive and respiratory ' 'syndrome virus in cultured porcine alveolar macrophages. Arch Virol. ' '2016;161:257–68. https://doi.org/10.1007/s00705-015-2653-2.', 'journal-title': 'Arch Virol.'}, { 'key': '336_CR35', 'doi-asserted-by': 'publisher', 'first-page': '192', 'DOI': '10.1177/1087057110390360.', 'volume': '16', 'author': 'KM Wagstaff', 'year': '2011', 'unstructured': 'Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA. An AlphaScreen(R)-based ' 'assay for high-throughput screening for specific inhibitors of nuclear ' 'import. J Biomol Screen. 2011;16:192–200. ' 'https://doi.org/10.1177/1087057110390360.', 'journal-title': 'J Biomol Screen'}, { 'key': '336_CR36', 'doi-asserted-by': 'publisher', 'first-page': '749', 'DOI': '10.2478/pjvs-2013-0106.', 'volume': '16', 'author': 'A Slonska', 'year': '2013', 'unstructured': 'Slonska A, Cymerys J, Skwarska J, Golke A, Banbura MW. Influence of ' 'importin alpha/beta and exportin 1 on equine herpesvirus type 1 (EHV-1) ' 'replication in primary murine neurons. Pol J Vet Sci. 2013;16:749–51. ' 'https://doi.org/10.2478/pjvs-2013-0106.', 'journal-title': 'Pol J Vet Sci'}, { 'key': '336_CR37', 'doi-asserted-by': 'publisher', 'first-page': '55', 'DOI': '10.1016/j.antiviral.2018.09.010.', 'volume': '159', 'author': 'C Lv', 'year': '2018', 'unstructured': 'Lv C, Liu W, Wang B, et al. Ivermectin inhibits DNA polymerase UL42 of ' 'pseudorabies virus entrance into the nucleus and proliferation of the ' 'virus in vitro and vivo. Antivir Res. 2018;159:55–62. ' 'https://doi.org/10.1016/j.antiviral.2018.09.010.', 'journal-title': 'Antivir Res.'}, { 'key': '336_CR38', 'doi-asserted-by': 'crossref', 'unstructured': 'Berthomme H, Monahan SJ, Parris DS, Jacquemont B, Epstein AL. Cloning, ' 'sequencing, and functional characterization of the two subunits of the ' 'pseudorabies virus DNA polymerase holoenzyme: evidence for specificity ' 'of interaction. J Virol. 1995 May;69(5):2811-8. PubMed PMID: 7707503; ' 'PubMed Central PMCID: PMC188975', 'DOI': '10.1128/jvi.69.5.2811-2818.1995'}, { 'key': '336_CR39', 'doi-asserted-by': 'publisher', 'first-page': '124.', 'DOI': '10.3389/fmicb.2016.00124.', 'volume': '7', 'author': 'Y-P Wang', 'year': '2016', 'unstructured': 'Wang Y-P, Du W-J, Huang L-P, et al. The pseudorabies virus DNA ' 'polymerase accessory subunit UL42 directs nuclear transport of the ' 'holoenzyme. Front Microbiol 2016;7:124. ' 'https://doi.org/10.3389/fmicb.2016.00124.', 'journal-title': 'Front Microbiol'}, { 'key': '336_CR40', 'doi-asserted-by': 'publisher', 'first-page': '110', 'DOI': '10.1016/j.virol.2014.10.013.', 'volume': '474', 'author': 'SM Bennett', 'year': '2015', 'unstructured': 'Bennett SM, Zhao L, Bosard C, Imperiale MJ. Role of a nuclear ' 'localization signal on the minor capsid proteins VP2 and VP3 in BKPyV ' 'nuclear entry. Virology. 2015;474:110–6. ' 'https://doi.org/10.1016/j.virol.2014.10.013.', 'journal-title': 'Virology.'}, { 'key': '336_CR41', 'doi-asserted-by': 'publisher', 'first-page': '80', 'DOI': '10.1016/j.virusres.2019.01.010.', 'volume': '263', 'author': 'X Wang', 'year': '2019', 'unstructured': 'Wang X, Lv C, Ji X, Wang B, Qiu L, Yang Z. Ivermectin treatment inhibits ' 'the replication of Porcine circovirus 2 (PCV2) in vitro and mitigates ' 'the impact of viral infection in piglets. Virus Res. 2019;263:80–6. ' 'https://doi.org/10.1016/j.virusres.2019.01.010.', 'journal-title': 'Virus Res.'}, { 'key': '336_CR42', 'doi-asserted-by': 'publisher', 'unstructured': 'Raza S, Shahin F, Zhai W, et al. Ivermectin inhibits bovine herpesvirus ' '1 DNA polymerase nuclear import and interferes with viral replication. ' 'Microorganisms. 2020;8. https://doi.org/10.3390/microorganisms8030409.', 'DOI': '10.3390/microorganisms8030409'}, { 'key': '336_CR43', 'unstructured': 'The FDA’s Center for Veterinary Medicine, ' 'https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans. ' 'Accessed 5 May 2020.'}, { 'key': '336_CR44', 'doi-asserted-by': 'publisher', 'first-page': '42', 'DOI': '10.1208/s12248-007-9000-9', 'volume': '10', 'author': 'AG Canga', 'year': '2008', 'unstructured': 'Canga AG, Prieto AM, Liébana MJ, Martínez NF, Vega MS, Vieitez JJ. The ' 'pharmacokinetics and interactions of ivermectin in humans—a mini-review. ' 'AAPS J. 2008;10:42–6.', 'journal-title': 'AAPS J'}, { 'key': '336_CR45', 'doi-asserted-by': 'publisher', 'first-page': '495', 'DOI': '10.1038/ja.2017.11', 'volume': '70', 'author': 'A Crump', 'year': '2017', 'unstructured': 'Crump A. Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to ' 'surprise and exceed expectations. J Antibiot. 2017;70:495–505.', 'journal-title': 'J Antibiot'}], 'container-title': 'The Journal of Antibiotics', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://www.nature.com/articles/s41429-020-0336-z.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://www.nature.com/articles/s41429-020-0336-z', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://www.nature.com/articles/s41429-020-0336-z.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 5, 20]], 'date-time': '2023-05-20T21:34:06Z', 'timestamp': 1684618446000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41429-020-0336-z'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 6, 12]]}, 'references-count': 45, 'journal-issue': {'issue': '9', 'published-print': {'date-parts': [[2020, 9]]}}, 'alternative-id': ['336'], 'URL': 'http://dx.doi.org/10.1038/s41429-020-0336-z', 'relation': {}, 'ISSN': ['0021-8820', '1881-1469'], 'subject': [], 'container-title-short': 'J Antibiot', 'published': {'date-parts': [[2020, 6, 12]]}, 'assertion': [ { 'value': '21 April 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '5 May 2020', 'order': 2, 'name': 'revised', 'label': 'Revised', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '17 May 2020', 'order': 3, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '12 June 2020', 'order': 4, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Compliance with ethical standards'}}, { 'value': 'The authors declare that they have no conflict of interest.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of interest'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit